ECSP19083343A - Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario - Google Patents

Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario

Info

Publication number
ECSP19083343A
ECSP19083343A ECSENADI201983343A ECDI201983343A ECSP19083343A EC SP19083343 A ECSP19083343 A EC SP19083343A EC SENADI201983343 A ECSENADI201983343 A EC SENADI201983343A EC DI201983343 A ECDI201983343 A EC DI201983343A EC SP19083343 A ECSP19083343 A EC SP19083343A
Authority
EC
Ecuador
Prior art keywords
antibody proteins
immune
related disorders
cytokines
methods
Prior art date
Application number
ECSENADI201983343A
Other languages
English (en)
Inventor
Yaiza Diaz-De-Durana
Shelly Meeusen
Glen Spraggon
Christophe Filippi
Michael Didonato
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP19083343A publication Critical patent/ECSP19083343A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/197—Treatment of whole grains not provided for in groups A23L7/117 - A23L7/196
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02B—PREPARING GRAIN FOR MILLING; REFINING GRANULAR FRUIT TO COMMERCIAL PRODUCTS BY WORKING THE SURFACE
    • B02B1/00—Preparing grain for milling or like processes
    • B02B1/04—Wet treatment, e.g. washing, wetting, softening
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/18—Adding fluid, other than for crushing or disintegrating by fluid energy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/18—Adding fluid, other than for crushing or disintegrating by fluid energy
    • B02C23/40—Adding fluid, other than for crushing or disintegrating by fluid energy with more than one means for adding fluid to the material being crushed or disintegrated
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C4/00—Crushing or disintegrating by roller mills
    • B02C4/02—Crushing or disintegrating by roller mills with two or more rollers
    • B02C4/06—Crushing or disintegrating by roller mills with two or more rollers specially adapted for milling grain
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C4/00—Crushing or disintegrating by roller mills
    • B02C4/10—Crushing or disintegrating by roller mills with a roller co-operating with a stationary member
    • B02C4/12—Crushing or disintegrating by roller mills with a roller co-operating with a stationary member in the form of a plate
    • B02C4/16—Crushing or disintegrating by roller mills with a roller co-operating with a stationary member in the form of a plate specially adapted for milling grain
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C9/00—Other milling methods or mills specially adapted for grain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C15/00—Disintegrating by milling members in the form of rollers or balls co-operating with rings or discs
    • B02C15/14—Edge runners, e.g. Chile mills
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona proteínas de anticuerpo injertadas con citocinas que se unen a la señalización intracelular y la estimulan a través de un receptor de interleucina de alta afinidad. Las proteínas de anticuerpo injertadas con citocinas hallan un uso en el aumento de las respuestas celulares antiinflamatorias y en la reducción los efectos pro-inflamatorios en el tratamiento, el alivio y la prevención de trastornos relacionados con el sistema inmunitario tales como diabetes Tipo 1.
ECSENADI201983343A 2017-05-24 2019-11-21 Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario ECSP19083343A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762510514P 2017-05-24 2017-05-24

Publications (1)

Publication Number Publication Date
ECSP19083343A true ECSP19083343A (es) 2019-11-30

Family

ID=62685010

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201983343A ECSP19083343A (es) 2017-05-24 2019-11-21 Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario

Country Status (25)

Country Link
US (3) US11122825B2 (es)
EP (1) EP3630812A1 (es)
JP (2) JP7093794B2 (es)
KR (1) KR102381237B1 (es)
CN (1) CN110650973B (es)
AR (1) AR112239A1 (es)
AU (2) AU2018274215B2 (es)
BR (1) BR112019024544A2 (es)
CA (1) CA3063527A1 (es)
CL (1) CL2019003392A1 (es)
CO (1) CO2019013000A2 (es)
CR (1) CR20190535A (es)
CU (1) CU20190093A7 (es)
EA (1) EA201992776A1 (es)
EC (1) ECSP19083343A (es)
IL (1) IL270772B2 (es)
JO (1) JOP20190271A1 (es)
MA (1) MA50433A (es)
MY (1) MY200872A (es)
PE (1) PE20200302A1 (es)
PH (1) PH12019502617A1 (es)
TW (1) TWI825020B (es)
UY (1) UY37738A (es)
WO (1) WO2018215935A1 (es)
ZA (1) ZA201907481B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
CZ20003099A3 (cs) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2369616C (en) * 1999-04-27 2009-09-15 Eurogen Holding, S.A. Somatic transgene immunization and related methods
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE320450T1 (de) 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
NZ536054A (en) 2002-04-09 2009-10-30 Scripps Research Inst Motif-grafted hybrid polypeptides and uses thereof
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004108078A2 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
US20060134098A1 (en) 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
WO2010099019A1 (en) 2009-02-24 2010-09-02 Alexion Pharmaceuticals, Inc. Antibodies containing therapeutic tpo/epo mimetic peptides
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
MX2013009151A (es) 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) * 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
WO2014138725A1 (en) 2013-03-08 2014-09-12 Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
KR102042246B1 (ko) * 2014-02-06 2019-11-28 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
MY193723A (en) 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
UY37003A (es) 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
UY37738A (es) 2019-01-02
AU2018274215A1 (en) 2019-12-12
RU2019142660A3 (es) 2021-10-05
CU20190093A7 (es) 2021-03-11
US20220346415A1 (en) 2022-11-03
AR112239A1 (es) 2019-10-09
EP3630812A1 (en) 2020-04-08
CN110650973B (zh) 2023-02-24
EA201992776A1 (ru) 2020-10-12
CA3063527A1 (en) 2018-11-29
BR112019024544A2 (pt) 2020-06-23
ZA201907481B (en) 2023-02-22
RU2019142660A (ru) 2021-06-24
CO2019013000A2 (es) 2020-01-17
IL270772A (en) 2020-01-30
AU2018274215B2 (en) 2021-10-28
TWI825020B (zh) 2023-12-11
CR20190535A (es) 2020-01-15
US20200113974A1 (en) 2020-04-16
PE20200302A1 (es) 2020-02-06
KR102381237B1 (ko) 2022-04-01
IL270772B2 (en) 2023-08-01
US20220039441A1 (en) 2022-02-10
JP2022130504A (ja) 2022-09-06
IL270772B1 (en) 2023-04-01
PH12019502617A1 (en) 2020-06-08
MY200872A (en) 2024-01-20
TW201900222A (zh) 2019-01-01
CL2019003392A1 (es) 2020-03-13
AU2022200528A1 (en) 2022-02-17
US11930837B2 (en) 2024-03-19
JOP20190271A1 (ar) 2019-11-21
JP2020520667A (ja) 2020-07-16
CN110650973A (zh) 2020-01-03
JP7093794B2 (ja) 2022-06-30
MA50433A (fr) 2020-09-02
KR20200008614A (ko) 2020-01-28
WO2018215935A1 (en) 2018-11-29
US11122825B2 (en) 2021-09-21

Similar Documents

Publication Publication Date Title
ECSP19083343A (es) Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario
ECSP18041733A (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
CL2017002110A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos (divisional solicitud 201502357)
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
CL2018003438A1 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos.
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
CL2015001941A1 (es) Los anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorias.
CL2016001968A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
DOP2018000019A (es) Inmunoconjugados de il22
PY1802434A (es) "anticuerpos anti-tgf-beta y su uso"
CL2018002006A1 (es) Anticuerpos anti-cd3 y métodos de uso (divisional solicitud 201601556)
AR105945A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y terapia del cáncer
UY35443A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina